146 related articles for article (PubMed ID: 35331739)
1. Rac GTPases in acute myeloid leukemia cells: Expression profile and biological effects of pharmacological inhibition.
Ramos DFV; Mancuso RI; Contieri B; Duarte A; Paiva L; de Melo Carrilho J; Saad STO; Lazarini M
Toxicol Appl Pharmacol; 2022 May; 442():115990. PubMed ID: 35331739
[TBL] [Abstract][Full Text] [Related]
2. Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis.
Tseng CY; Fu YH; Ou DL; Lu JW; Hou HA; Lin LI
Cancer Gene Ther; 2023 Dec; 30(12):1691-1701. PubMed ID: 37821641
[TBL] [Abstract][Full Text] [Related]
3. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
4. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
[TBL] [Abstract][Full Text] [Related]
5. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
[TBL] [Abstract][Full Text] [Related]
6. Bone mesenchymal stem cell-derived exosomal microRNA-7-5p inhibits progression of acute myeloid leukemia by targeting OSBPL11.
Jiang D; Wu X; Sun X; Tan W; Dai X; Xie Y; Du A; Zhao Q
J Nanobiotechnology; 2022 Jan; 20(1):29. PubMed ID: 35012554
[TBL] [Abstract][Full Text] [Related]
7. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
8. Long non‑coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells.
Yang Y; Dai W; Sun Y; Zhao Z
Oncol Rep; 2019 Apr; 41(4):2311-2320. PubMed ID: 30720129
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of PI3K-AKT-mTOR pathway and modulation of histone deacetylase enzymes reduce the growth of acute myeloid leukemia cells.
Şansaçar M; Sağır H; Gencer Akçok EB
Med Oncol; 2023 Dec; 41(1):31. PubMed ID: 38148433
[TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
[TBL] [Abstract][Full Text] [Related]
11. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
12. Regulatory role of RBM39 in acute myeloid leukemia: Mediation through the PI3K/AKT pathway.
Zhang X; Yang L; Liu X; Nie Z; Liu M; Wang T; Lu Y; Pan Y; Zhan Y; Wang Z; Luo J
Biochim Biophys Acta Mol Cell Res; 2024 Jan; 1871(1):119607. PubMed ID: 37852323
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
[TBL] [Abstract][Full Text] [Related]
14. Prazosin inhibits the proliferation and survival of acute myeloid leukaemia cells through down-regulating TNS1.
Sun X; Yang S; Song W
Biomed Pharmacother; 2020 Apr; 124():109731. PubMed ID: 31954876
[TBL] [Abstract][Full Text] [Related]
15. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
[TBL] [Abstract][Full Text] [Related]
16. Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases.
Shutes A; Onesto C; Picard V; Leblond B; Schweighoffer F; Der CJ
J Biol Chem; 2007 Dec; 282(49):35666-78. PubMed ID: 17932039
[TBL] [Abstract][Full Text] [Related]
17. SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
Meng H; Jin Y; Liu H; You L; Yang C; Yang X; Qian W
J Hematol Oncol; 2013 Feb; 6():18. PubMed ID: 23415012
[TBL] [Abstract][Full Text] [Related]
18. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
Brenner AK; Andersson Tvedt TH; Bruserud Ø
Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
[TBL] [Abstract][Full Text] [Related]
19. Kinesin family member 2A acts as a potential prognostic marker and treatment target via interaction with PI3K/AKT and RhoA/ROCK pathways in acute myeloid leukemia.
Liang X; Xia R
Oncol Rep; 2022 Jan; 47(1):. PubMed ID: 34792179
[TBL] [Abstract][Full Text] [Related]
20. The simultaneous inhibition of the mTOR and MAPK pathways with Gnetin-C induces apoptosis in acute myeloid leukemia.
Espinoza JL; Elbadry MI; Taniwaki M; Harada K; Trung LQ; Nakagawa N; Takami A; Ishiyama K; Yamauchi T; Takenaka K; Nakao S
Cancer Lett; 2017 Aug; 400():127-136. PubMed ID: 28456658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
